

Enrica Marchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5583906/publications.pdf>

Version: 2024-02-01

34
papers

934
citations

759233

12
h-index

501196

28
g-index

34
all docs

34
docs citations

34
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 4293-4297.	1.6	268
2	Gemcitabine as frontline treatment for cutaneous Tâ€cell lymphoma. <i>Cancer</i> , 2005, 104, 2437-2441.	4.1	149
3	A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. <i>Blood</i> , 2018, 131, 397-407.	1.4	109
4	Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. <i>Blood</i> , 2019, 134, 1395-1405.	1.4	100
5	The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 215-226.	2.5	51
6	The rapidly changing landscape in mature Tâ€cell lymphoma (MTCL) biology and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 47-70.	329.8	45
7	Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action. <i>Journal of Cancer Science & Therapy</i> , 2013, 5, 334-342.	1.7	41
8	Pralatrexate Pharmacology and Clinical Development. <i>Clinical Cancer Research</i> , 2013, 19, 6657-6661.	7.0	35
9	Survival benefit in patients with peripheral Tâ€cell lymphomas after treatments with novel therapies and clinical trials. <i>Hematological Oncology</i> , 2020, 38, 51-58.	1.7	24
10	The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in <i>in vivo</i> and <i>in vitro</i> models of aggressive large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2945-2952.	1.3	17
11	Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 227-235.	2.5	14
12	Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky038.	2.9	12
13	New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. <i>Expert Review of Hematology</i> , 2019, 12, 137-146.	2.2	12
14	Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 359-375.	2.2	9
15	The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma. <i>Oncotarget</i> , 2020, 11, 1576-1589.	1.8	8
16	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2006, 108, 2431-2431.	1.4	6
17	Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate. <i>Blood</i> , 2016, 128, 4149-4149.	1.4	5
18	Phase II Study of Proteasome Inhibitor Bortezomib (Velcade®) in Patients with Relapsed/Refractory T-Cell Lymphoma: Preliminary Results.. <i>Blood</i> , 2006, 108, 2462-2462.	1.4	4

#	ARTICLE	IF	CITATIONS
19	The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 646-646.	1.4	4
20	Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 639-651.	2.8	3
21	Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL). <i>Blood</i> , 2018, 132, 1002-1002.	1.4	3
22	Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development. <i>Blood</i> , 2015, 126, 1282-1282.	1.4	3
23	The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8049-8049.	1.6	3
24	<i>Peripheral T-Cell Lymphoma Involvement of the Central Nervous System: Impact of Novel Therapeutics on Clinical Outcomes</i>. <i>Blood</i> , 2021, 138, 2469-2469.	1.4	3
25	Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072094734.	2.5	2
26	Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 3014-3017.	1.3	2
27	Report of a Phase II Study of Proteasome Inhibitor Bortezomib (Velcade) in Patients with Relapsed or Refractory T-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 4764-4764.	1.4	1
28	Bone marrow aspirate quality assessment.. <i>Journal of Clinical Oncology</i> , 2017, 35, 76-76.	1.6	1
29	A Phase II Trial of CHOP Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients.. <i>Blood</i> , 2005, 106, 4765-4765.	1.4	0
30	A Phase II Trial of FM (Oral Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) for Previously Untreated Follicular Lymphoma (FL) Patients.. <i>Blood</i> , 2005, 106, 4763-4763.	1.4	0
31	A Phase II Trial of FM (Fludarabine and Mitoxantrone) Chemotherapy Followed by Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for Previously Untreated Indolent Non-Follicular Lymphoma Patients.. <i>Blood</i> , 2006, 108, 2478-2478.	1.4	0
32	Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.. <i>Blood</i> , 2012, 120, 2725-2725.	1.4	0
33	Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response. <i>Blood</i> , 2013, 122, 4430-4430.	1.4	0
34	A survey of cancer testis antigen (CTA) expression across T-cell lymphoma subtypes.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15246-e15246.	1.6	0